{"id":55269,"date":"2026-02-07T00:33:14","date_gmt":"2026-02-06T23:33:14","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2026\/02\/07\/neoadjuvant-endocrine-treatment-plus-mammaglobin-a-dna-vaccine-induces-antitumor-immune-responses-in-the-primary-tumor-and-peripheral-blood-of-breast-cancer-patients-insights-from-a-phase-1b-clinical\/"},"modified":"2026-02-07T00:33:14","modified_gmt":"2026-02-06T23:33:14","slug":"neoadjuvant-endocrine-treatment-plus-mammaglobin-a-dna-vaccine-induces-antitumor-immune-responses-in-the-primary-tumor-and-peripheral-blood-of-breast-cancer-patients-insights-from-a-phase-1b-clinical","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2026\/02\/07\/neoadjuvant-endocrine-treatment-plus-mammaglobin-a-dna-vaccine-induces-antitumor-immune-responses-in-the-primary-tumor-and-peripheral-blood-of-breast-cancer-patients-insights-from-a-phase-1b-clinical\/","title":{"rendered":"Neoadjuvant endocrine treatment plus mammaglobin-A DNA vaccine induces antitumor immune responses in the primary tumor and peripheral blood of breast cancer patients: Insights from a phase 1b clinical trial"},"content":{"rendered":"<div>\n<p><b>Cancer Immunol Res<\/b>. 2026 Feb 6. doi: 10.1158\/2326-6066.CIR-25-0666. Online ahead of print.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Tumor-associated antigen (TAA) vaccines are being explored as a strategy to induce antitumor immune responses. Mammaglobin-A (Mam-A) is a TAA expressed in &gt;50% of breast cancer (BC) patients. Previously, we have shown that Mam-A DNA vaccines induce antitumor immune responses in patients with stable metastatic disease. To further evaluate the potential of the Mam-A vaccine, we initiated a phase-1b clinical trial in estrogen receptor-positive BC patients prior to surgery. Eight patients were assigned to Arm 1 (neoadjuvant endocrine therapy alone) and 17 to Arm 2 (neoadjuvant endocrine therapy plus Mam-A vaccination); the final analysis included 8 patients from Arm 1 and 13 from Arm 2. Ex vivo ELISpot analysis of peripheral blood mononuclear cells demonstrated that Mam-A vaccination induced Mam-A-specific T cells in 8\/13 patients. Intracellular cytokine staining, and Mam-A-specific tetramer staining revealed that vaccine-induced Mam-A-specific T cells included both CD4+ and CD8+ polyfunctional T cells. Finally, high-throughput imaging mass cytometry identified 24 cellular meta-clusters with features of tumor, immune, stromal, and endothelial cells and revealed an increased CD8+ T-cell prevalence in the tumor after Mam-A vaccination. In particular, vaccination was associated with the infiltration of PD-1+CD8+ T cells. In addition, post-vaccination tumor samples exhibited close spatial interactions between cytotoxic CD8+ T cells (CTL) and Mam-A+ tumor cells and between CTL and antigen-experienced CD4+ T cells. Together, these results suggest that Mam-A DNA vaccination elicits both systemic and intratumoral antitumor immune responses.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41650206\/?utm_source=SimplePie&amp;utm_medium=rss&amp;utm_content=101614637&amp;ff=20260206183309&amp;v=2.18.0.post22+67771e2\">41650206<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1158\/2326-6066.CIR-25-0666\">10.1158\/2326-6066.CIR-25-0666<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Cancer Immunol Res. 2026 Feb 6. doi: 10.1158\/2326-6066.CIR-25-0666. Online ahead of print. ABSTRACT Tumor-associated antigen (TAA) vaccines are being explored as a strategy to induce antitumor immune responses. Mammaglobin-A (Mam-A) is a TAA expressed in &gt;50% of breast cancer (BC) patients. Previously, we have shown that Mam-A DNA vaccines induce antitumor immune responses in patients &#8230; <a title=\"Neoadjuvant endocrine treatment plus mammaglobin-A DNA vaccine induces antitumor immune responses in the primary tumor and peripheral blood of breast cancer patients: Insights from a phase 1b clinical trial\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/07\/neoadjuvant-endocrine-treatment-plus-mammaglobin-a-dna-vaccine-induces-antitumor-immune-responses-in-the-primary-tumor-and-peripheral-blood-of-breast-cancer-patients-insights-from-a-phase-1b-clinical\/\" aria-label=\"Read more about Neoadjuvant endocrine treatment plus mammaglobin-A DNA vaccine induces antitumor immune responses in the primary tumor and peripheral blood of breast cancer patients: Insights from a phase 1b clinical trial\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[55,42],"tags":[],"class_list":["post-55269","post","type-post","status-publish","format-standard","hentry","category-cancer-immunology-reserch","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/55269","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=55269"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/55269\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=55269"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=55269"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=55269"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}